Parkinson disease (PD) affects up to 10 million people worldwide and is clinically diagnosed. Molecular phenotyping of patient samples might help to corroborate diagnosis, and a new study suggests that blood-based gene expression profiling might distinguish between patients with PD and those without. However, experience suggests that additional replication is needed.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Multi-modality machine learning predicting Parkinson’s disease
npj Parkinson's Disease Open Access 01 April 2022
-
Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures
npj Systems Biology and Applications Open Access 27 October 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Adler, C. H. et al. Low clinical diagnostic accuracy of early versus advanced Parkinson disease: clinicopathologic study. Neurology 83, 406–412 (2014).
Shamir, R. et al. Analysis of blood-based gene expression in idiopathic Parkinson disease. Neurology 89, 1676–1683 (2017).
Scherzer, C. R. et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl Acad. Sci. USA 104, 955–960 (2007).
Soreq, L., Israel, Z., Bergman, H. & Soreq, H. Advanced microarray analysis highlights modified neuro-immune signaling in nucleated blood cells from Parkinson's disease patients. J. Neuroimmunol. 201–202, 227–236 (2008).
Molochnikov, L. et al. A molecular signature in blood identifies early Parkinson's disease. Mol. Neurodegener. 7, 26 (2012).
Santiago, J. A. & Potashkin, J. A. Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease. Proc. Natl Acad. Sci. USA 112, 2257–2262 (2015).
Santiago, J. A. & Potashkin, J. A. Blood biomarkers associated with cognitive decline in early stage and drug-naive parkinson's disease patients. PLOS ONE 10, e0142582 (2015).
Cummings, J. L. et al. The role of dopaminergic imaging in patients with symptoms of dopaminergic system neurodegeneration. Brain 134, 3146–3166 (2011).
Marek, K. et al. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629–635 (2011).
Chen-Plotkin, A. S. Unbiased approaches to biomarker discovery in neurodegenerative diseases. Neuron 84, 594–607 (2014).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Chen-Plotkin, A. Blood transcriptomics for Parkinson disease?. Nat Rev Neurol 14, 5–6 (2018). https://doi.org/10.1038/nrneurol.2017.166
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.166
This article is cited by
-
Multi-modality machine learning predicting Parkinson’s disease
npj Parkinson's Disease (2022)
-
Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures
npj Systems Biology and Applications (2021)
-
Deep sequencing of sncRNAs reveals hallmarks and regulatory modules of the transcriptome during Parkinson’s disease progression
Nature Aging (2021)
